Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för canertinib dihydrochloride. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

7 träffar

Bibliografisk träff 2016-08-22

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.

Smaill JB, Gonzales AJ, Spicer JA, Lee H, Reed JE, Sexton K, Althaus IW, Zhu T, Black SL, Blaser A, Denny WA, Ellis PA, Fakhoury S, Harvey PJ, Hook K, McCarthy FO, Palmer BD, Rivault F, Schlosser K, Ellis T, Thompson AM, Trachet E, Winters RT, Tecle H, Bridges A.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.6b00883

Bibliografisk träff 2011-03-03

Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

Shallal HM, Russu WA.

Eur J Med Chem · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ejmech.2011.02.057

Bibliografisk träff 2007-12-01

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA.

Cancer Res · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-07-1885

Bibliografisk träff 2006-02-01

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA, Roberts BJ, Fry DW, Gonzales AJ, Harvey PJ, Nelson JM, Sherwood V, Han HK, Pace G, Smaill JB, Denny WA, Showalter HD.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm050936o

Bibliografisk träff 2003-10-01

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.

Allen LF, Eiseman IA, Fry DW, Lenehan PF.

Semin Oncol · review; journal article · DOI 10.1053/j.seminoncol.2003.08.009

Bibliografisk träff 2001-10-01

CI-1033, a pan-erbB tyrosine kinase inhibitor.

Slichenmyer WJ, Elliott WL, Fry DW.

Semin Oncol · review; journal article · DOI 10.1016/s0093-7754(01)90285-4

Bibliografisk träff 2001-02-01

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.

Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, Nelson JM, Sherwood V, Vincent PW, Roberts BJ, Elliott WL, Denny WA.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm000372i